These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29321031)

  • 1. Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice - the ECSTATIC study: a cluster randomised non-inferiority trial.
    Luymes CH; Poortvliet RKE; van Geloven N; de Waal MWM; Drewes YM; Blom JW; Smidt N; Assendelft WJJ; van den Hout WB; de Ruijter W; Numans ME
    BMC Med; 2018 Jan; 16(1):5. PubMed ID: 29321031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deprescribing Potentially Inappropriate Preventive Cardiovascular Medication: Barriers and Enablers for Patients and General Practitioners.
    Luymes CH; van der Kleij RM; Poortvliet RK; de Ruijter W; Reis R; Numans ME
    Ann Pharmacother; 2016 Jun; 50(6):446-54. PubMed ID: 26939589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
    Palmer MJ; Machiyama K; Woodd S; Gubijev A; Barnard S; Russell S; Perel P; Free C
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD012675. PubMed ID: 33769555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
    Palmer MJ; Barnard S; Perel P; Free C
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012675. PubMed ID: 29932455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a multicomponent communication training to involve older people in decisions to DEPRESCRIBE cardiometabolic medication in primary care (CO-DEPRESCRIBE): protocol for a cluster randomized controlled trial with embedded process and economic evaluation.
    Stuijt PJC; Heringa M; van Dijk L; Faber A; Burgers JS; Feenstra TL; Taxis K; Denig P
    BMC Prim Care; 2024 Jun; 25(1):210. PubMed ID: 38862899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How general practitioners would deprescribe in frail oldest-old with polypharmacy - the LESS study.
    Mantelli S; Jungo KT; Rozsnyai Z; Reeve E; Luymes CH; Poortvliet RKE; Chiolero A; Rodondi N; Gussekloo J; Streit S
    BMC Fam Pract; 2018 Oct; 19(1):169. PubMed ID: 30314468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk scoring for the primary prevention of cardiovascular disease.
    Karmali KN; Persell SD; Perel P; Lloyd-Jones DM; Berendsen MA; Huffman MD
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006887. PubMed ID: 28290160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study.
    Simmons RK; Borch-Johnsen K; Lauritzen T; Rutten GE; Sandbæk A; van den Donk M; Black JA; Tao L; Wilson EC; Davies MJ; Khunti K; Sharp SJ; Wareham NJ; Griffin SJ
    Health Technol Assess; 2016 Aug; 20(64):1-86. PubMed ID: 27583404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Peterson GG; Pu J; Magid DJ; Barterian L; Kranker K; Barna M; Conwell L; Rose A; Blue L; Markovitz A; McCall N; Markovich P
    JAMA Cardiol; 2021 Sep; 6(9):1050-1059. PubMed ID: 34076665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of a protocol for deprescribing antihypertensive medication in older patients in Dutch general practices.
    Hassan D; Versmissen J; Hek K; van Dijk L; van den Bemt PMLA
    BMC Prim Care; 2022 Nov; 23(1):280. PubMed ID: 36352363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease.
    Redfern J; Tu Q; Hyun K; Hollings MA; Hafiz N; Zwack C; Free C; Perel P; Chow CK
    Cochrane Database Syst Rev; 2024 Mar; 3(3):CD011851. PubMed ID: 38533994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a multifaceted intervention on cardiovascular risk factors in high-risk hypertensive patients: the ESCAPE trial, a pragmatic cluster randomized trial in general practice.
    Pouchain D; Lièvre M; Huas D; Lebeau JP; Renard V; Bruckert E; Girerd X; Boutitie F;
    Trials; 2013 Oct; 14():318. PubMed ID: 24083783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the Ready to Reduce Risk (3R) complex intervention for the primary prevention of cardiovascular disease: a pragmatic randomised controlled trial.
    Byrne JL; Dallosso HM; Rogers S; Gray LJ; Waheed G; Patel P; Gupta P; Doherty Y; Davies MJ; Khunti K
    BMC Med; 2020 Jul; 18(1):198. PubMed ID: 32713349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OPtimising Treatment for MIld Systolic hypertension in the Elderly (OPTiMISE): protocol for a randomised controlled non-inferiority trial.
    Sheppard JP; Burt J; Lown M; Temple E; Benson J; Ford GA; Heneghan C; Hobbs FDR; Jowett S; Little P; Mant J; Mollison J; Nickless A; Ogburn E; Payne R; Williams M; Yu LM; McManus RJ
    BMJ Open; 2018 Oct; 8(9):e022930. PubMed ID: 30287610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-dose combination therapy for the prevention of cardiovascular disease.
    de Cates AN; Farr MR; Wright N; Jarvis MC; Rees K; Ebrahim S; Huffman MD
    Cochrane Database Syst Rev; 2014 Apr; 4(4):CD009868. PubMed ID: 24737108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease.
    Rees K; Takeda A; Martin N; Ellis L; Wijesekara D; Vepa A; Das A; Hartley L; Stranges S
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD009825. PubMed ID: 30864165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease.
    Schmucker C; Eisele-Metzger A; Meerpohl JJ; Lehane C; Kuellenberg de Gaudry D; Lohner S; Schwingshackl L
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD013556. PubMed ID: 35199850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
    Selak V; Elley CR; Bullen C; Crengle S; Wadham A; Rafter N; Parag V; Harwood M; Doughty RN; Arroll B; Milne RJ; Bramley D; Bryant L; Jackson R; Rodgers A
    BMJ; 2014 May; 348():g3318. PubMed ID: 24868083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deprescribing Education vs Usual Care for Patients With Cognitive Impairment and Primary Care Clinicians: The OPTIMIZE Pragmatic Cluster Randomized Trial.
    Bayliss EA; Shetterly SM; Drace ML; Norton JD; Maiyani M; Gleason KS; Sawyer JK; Weffald LA; Green AR; Reeve E; Maciejewski ML; Sheehan OC; Wolff JL; Kraus C; Boyd CM
    JAMA Intern Med; 2022 May; 182(5):534-542. PubMed ID: 35343999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.